11C-acetate/18Fluorodeoxyglucose-FDG PET/CT and Cardiac MRI in Pulmonary Hypertension
| Status: | Completed |
|---|---|
| Conditions: | High Blood Pressure (Hypertension), High Blood Pressure (Hypertension) |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - 80 |
| Updated: | 2/7/2019 |
| Start Date: | August 2013 |
| End Date: | October 2018 |
Evaluation of Regional Myocardial Perfusion, Glucose Utilization and Oxidative Metabolism in Patients With Pulmonary Hypertension Using Combined [11C]Acetate and [18F]Fluorodeoxyglucose (FDG) PET/CT and Cardiovascular MRI
This study is looking at differences in metabolism and functional imaging between pulmonary
hypertension subjects with normal right ventricular function and persistent right ventricular
dysfunction.
hypertension subjects with normal right ventricular function and persistent right ventricular
dysfunction.
We will measure right ventricular metabolic and structural changes using serial 11C-acetate
and 18F-FDG PET/CT and cardiac MRI as response to treatment with ranolazine. Subjects undergo
imaging procedures at week 0 and week 26 (optional for normal function patients). This is a
companion imaging trial for patients who are eligible for the treatment trial entitled "A
randomized, double-blind, placebo controlled, multi-center study to assess the effect of
ranolazine on outcomes in subjects with pulmonary hypertension and right ventricular
dysfunction accompanied by a comparative study of cellular metabolism in subjects with
pulmonary hypertension with and without right ventricular dysfunction". Subjects must enroll
in companion treatment protocol to qualify for the imaging protocol.
The cardiac MRI portion of the study continued, but the PET portion of the study was
discontinued due to funding.
The treatment protocol is registered under: NCT01839110. Due to funding issues, the completed
study was registered under NCT02829034.
and 18F-FDG PET/CT and cardiac MRI as response to treatment with ranolazine. Subjects undergo
imaging procedures at week 0 and week 26 (optional for normal function patients). This is a
companion imaging trial for patients who are eligible for the treatment trial entitled "A
randomized, double-blind, placebo controlled, multi-center study to assess the effect of
ranolazine on outcomes in subjects with pulmonary hypertension and right ventricular
dysfunction accompanied by a comparative study of cellular metabolism in subjects with
pulmonary hypertension with and without right ventricular dysfunction". Subjects must enroll
in companion treatment protocol to qualify for the imaging protocol.
The cardiac MRI portion of the study continued, but the PET portion of the study was
discontinued due to funding.
The treatment protocol is registered under: NCT01839110. Due to funding issues, the completed
study was registered under NCT02829034.
Inclusion Criteria:
Participation in the companion treatment protocol "A randomized, double-blind, placebo
controlled, multi-center study to assess the effect of ranolazine on outcomes in subjects
with pulmonary hypertension and right ventricular dysfunction accompanied by a comparative
study of cellular metabolism in subjects with pulmonary hypertension with and without right
ventricular dysfunction"
Exclusion Criteria:
- Pregnancy or lactation: Women of childbearing potential must have a negative urine or
blood pregnancy test on the day of the PET/CT scan.
- Severe anxiety or claustrophobia prohibiting completion of imaging
- Inability to tolerate imaging procedures (1 hour MRI, 30 min and 15 min PET)
- Implantable cardioverter-defibrillator, Pacemaker, hazardous metallic implants or any
other contraindication to MRI.
- Uncontrolled diabetes mellitus with fasting glucose > 150 mg/dL
We found this trial at
1
site
Univ of Pennsylvania Penn has a long and proud tradition of intellectual rigor and pursuit...
Click here to add this to my saved trials
